302 related articles for article (PubMed ID: 24140246)
1. Gene-based urinary biomarkers for bladder cancer: an unfulfilled promise?
Sapre N; Anderson PD; Costello AJ; Hovens CM; Corcoran NM
Urol Oncol; 2014 Jan; 32(1):48.e9-17. PubMed ID: 24140246
[TBL] [Abstract][Full Text] [Related]
2. Urine markers for detection and surveillance of non-muscle-invasive bladder cancer.
Tilki D; Burger M; Dalbagni G; Grossman HB; Hakenberg OW; Palou J; Reich O; Rouprêt M; Shariat SF; Zlotta AR
Eur Urol; 2011 Sep; 60(3):484-92. PubMed ID: 21684071
[TBL] [Abstract][Full Text] [Related]
3. Potential of urinary biomarkers in early bladder cancer diagnosis.
Lam T; Nabi G
Expert Rev Anticancer Ther; 2007 Aug; 7(8):1105-15. PubMed ID: 18028019
[TBL] [Abstract][Full Text] [Related]
4. [Bladder cancer biomarkers].
Dobrowolska-Glazar B; Glazar W; Dobrowolski Z; Lipczyński W
Przegl Lek; 2010; 67(7):479-83. PubMed ID: 21387760
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in bladder cancer diagnostics.
Sanchez-Carbayo M
Clin Biochem; 2004 Jul; 37(7):562-71. PubMed ID: 15234237
[TBL] [Abstract][Full Text] [Related]
6. A 3-plex methylation assay combined with the FGFR3 mutation assay sensitively detects recurrent bladder cancer in voided urine.
Kandimalla R; Masius R; Beukers W; Bangma CH; Orntoft TF; Dyrskjot L; van Leeuwen N; Lingsma H; van Tilborg AA; Zwarthoff EC
Clin Cancer Res; 2013 Sep; 19(17):4760-9. PubMed ID: 23842048
[TBL] [Abstract][Full Text] [Related]
7. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
[TBL] [Abstract][Full Text] [Related]
8. Comparative predictive values of urinary cytology, urinary bladder cancer antigen, CYFRA 21-1 and NMP22 for evaluating symptomatic patients at risk for bladder cancer.
Sánchez-Carbayo M; Urrutia M; Silva JM; Romaní R; De Buitrago JM; Navajo JA
J Urol; 2001 May; 165(5):1462-7. PubMed ID: 11342897
[TBL] [Abstract][Full Text] [Related]
9. NMP-22, urinary cytology, and cystoscopy: a 1 year comparison study.
Schlake A; Crispen PL; Cap AP; Atkinson T; Davenport D; Preston DM
Can J Urol; 2012 Aug; 19(4):6345-50. PubMed ID: 22892257
[TBL] [Abstract][Full Text] [Related]
10. Combination analysis of hypermethylated Wnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection.
Urakami S; Shiina H; Enokida H; Kawakami T; Kawamoto K; Hirata H; Tanaka Y; Kikuno N; Nakagawa M; Igawa M; Dahiya R
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2109-16. PubMed ID: 16609023
[TBL] [Abstract][Full Text] [Related]
11. Methylation of a panel of microRNA genes is a novel biomarker for detection of bladder cancer.
Shimizu T; Suzuki H; Nojima M; Kitamura H; Yamamoto E; Maruyama R; Ashida M; Hatahira T; Kai M; Masumori N; Tokino T; Imai K; Tsukamoto T; Toyota M
Eur Urol; 2013 Jun; 63(6):1091-100. PubMed ID: 23200812
[TBL] [Abstract][Full Text] [Related]
12. Molecular biomarkers for predicting outcomes in urothelial carcinoma of the bladder.
Sapre N; Herle P; Anderson PD; Corcoran NM; Hovens CM
Pathology; 2014 Jun; 46(4):274-82. PubMed ID: 24798156
[TBL] [Abstract][Full Text] [Related]
13. Urinary bladder tumor markers.
Lokeshwar VB; Selzer MG
Urol Oncol; 2006; 24(6):528-37. PubMed ID: 17138134
[TBL] [Abstract][Full Text] [Related]
14. miR-143, miR-222, and miR-452 are useful as tumor stratification and noninvasive diagnostic biomarkers for bladder cancer.
Puerta-Gil P; García-Baquero R; Jia AY; Ocaña S; Alvarez-Múgica M; Alvarez-Ossorio JL; Cordon-Cardo C; Cava F; Sánchez-Carbayo M
Am J Pathol; 2012 May; 180(5):1808-15. PubMed ID: 22426337
[TBL] [Abstract][Full Text] [Related]
15. Developing biomarkers for improved diagnosis and treatment outcome monitoring of bladder cancer.
Lintula S; Hotakainen K
Expert Opin Biol Ther; 2010 Aug; 10(8):1169-80. PubMed ID: 20446896
[TBL] [Abstract][Full Text] [Related]
16. Genome-wide analysis of CpG island methylation in bladder cancer identified TBX2, TBX3, GATA2, and ZIC4 as pTa-specific prognostic markers.
Kandimalla R; van Tilborg AA; Kompier LC; Stumpel DJ; Stam RW; Bangma CH; Zwarthoff EC
Eur Urol; 2012 Jun; 61(6):1245-56. PubMed ID: 22284968
[TBL] [Abstract][Full Text] [Related]
17. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection.
Hoque MO; Begum S; Topaloglu O; Chatterjee A; Rosenbaum E; Van Criekinge W; Westra WH; Schoenberg M; Zahurak M; Goodman SN; Sidransky D
J Natl Cancer Inst; 2006 Jul; 98(14):996-1004. PubMed ID: 16849682
[TBL] [Abstract][Full Text] [Related]
18. Genetic and epigenetic biomarkers for early detection, therapeutic effectiveness and relapse monitoring in bladder cancer.
Dumache R; David D; Kaycsa A; Minciu R; Negru S; Puiu M
Rev Med Chir Soc Med Nat Iasi; 2011; 115(1):163-7. PubMed ID: 21682190
[TBL] [Abstract][Full Text] [Related]
19. Molecular markers for detection, surveillance and prognostication of bladder cancer.
Vrooman OP; Witjes JA
Int J Urol; 2009 Mar; 16(3):234-43. PubMed ID: 19298346
[TBL] [Abstract][Full Text] [Related]
20. Urinary biomarkers of bladder cancer: an update and future perspectives.
Rosser CJ; Urquidi V; Goodison S
Biomark Med; 2013 Oct; 7(5):779-90. PubMed ID: 24044570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
